About Antipsychotic Drugs
Antipsychotic drugs are also called as major tranquilizers or neuroleptics. These drugs are primarily used for the treatment of psychiatric disorders such as schizophrenia, hallucinations, delusions, bipolar disorder, and others. The antipsychotic drugs market is expected to grow due to the rising number of schizophrenic patients.
Technavio’s analysts forecast the global antipsychotic drugs market to grow at a CAGR of 1.84% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global antipsychotic drugs market for 2017-2021. To calculate the market size, the report considers sales from both branded and generic drugs.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Antipsychotic Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• AstraZeneca
• Eli Lilly
• GlaxoSmithKline
• Johnson & Johnson
Other prominent vendors
• Actavis Generics (a subsidiary of Teva Pharmaceutical Industries)
• Alkermes
• Bristol-Myers Squibb
Market driver
• Increasing expenditure on prescription drugs
• For a full, detailed list, view our report
Market challenge
• Lack of standard diagnostic methods
• For a full, detailed list, view our report
Market trend
• Rising public interest toward mental health
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
• Market outline
PART 05: Disease overview
• Psychosis
• Symptoms of psychiatric disorder
• Causes of psychiatric disorder
• Treatment of psychiatric disorder
• Medical use of antipsychotic drugs
PART 06: Key clinical trials
• Key clinical trials
PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 08: Market segmentation by disease type
• Market overview based on disease type
• Schizophrenia
• Bipolar disorder
• Unipolar depression
• Dementia
• Others
PART 09: Market segmentation based on MoA
• Market overview based on MoA
• First-generation antipsychotic drugs market
• Second-generation antipsychotic drugs market
• Third generation antipsychotic drugs market
PART 10: Geographical segmentation
• Market overview based on geography
• Antipsychotic drugs market in Americas
• Antipsychotic drugs market in EMEA
• Antipsychotic drugs market in APAC
PART 11: Decision framework
PART 12: Drivers and challenges
• Market drivers
• Market challenges
PART 13: Market trends
• Rising public interest toward mental health
• Increase in use of LAI antipsychotic drugs
• Antipsychotics with novel MoA
PART 14: Vendor landscape
• Competitive landscape
PART 15: Key vendor analysis
• AstraZeneca
• Eli Lilly
• GlaxoSmithKline
• Johnson & Johnson
• Other prominent vendors
PART 16: Appendix
• List of abbreviations
List of Exhibits
Exhibit 01: Reduction in prescription revenue over the years for antipsychotic drugs due to entry of generics
Exhibit 02: Signs and symptoms of psychiatric disorder
Exhibit 03: Causes of psychiatric disorder
Exhibit 04: List of medical conditions in which antipsychotic drugs used for the treatment
Exhibit 05: Stages of key clinical trials in global antipsychotic drugs market 2016
Exhibit 06: Snapshot of pipeline trends in global antipsychotic drugs market
Exhibit 07: Global antipsychotic drugs market 2016-2021 ($ millions)
Exhibit 08: Global antipsychotic drugs market: Opportunity analysis
Exhibit 09: Five forces analysis
Exhibit 10: Segmentation of global antipsychotic drugs market by disease type
Exhibit 11: Market share of global antipsychotic drugs market by disease type 2016
Exhibit 12: Global antipsychotic drugs market segmentation based on MoA 2016
Exhibit 13: Global first-generation antipsychotic drugs market 2016-2021 ($ millions)
Exhibit 14: Global second-generation antipsychotic drugs market 2016-2021 ($ millions)
Exhibit 15: Global third-generation antipsychotic drugs market 2016-2021 ($ millions)
Exhibit 16: Segmentation of global antipsychotic drugs market by geography 2016 and 2021
Exhibit 17: Global antipsychotic drugs market revenue by geography 2016-2021 ($ millions)
Exhibit 18: Global antipsychotic drugs market share by geography 2016-2021
Exhibit 19: Market scenario in Americas
Exhibit 20: Antipsychotic drugs market in Americas 2016-2021 ($ millions)
Exhibit 21: Market scenario in EMEA
Exhibit 22: Antipsychotic drugs market in EMEA 2016-2021 ($ millions)
Exhibit 23: Market scenario in APAC
Exhibit 24: Antipsychotic drugs market in APAC 2016-2021 ($ millions)
Exhibit 25: Competitive structure analysis of global antipsychotic drugs market 2016
Exhibit 26: AstraZeneca: Strength assessment
Exhibit 27: AstraZeneca: Strategy assessment
Exhibit 28: AstraZeneca: Opportunity assessment
Exhibit 29: AstraZeneca: Year-over-year (YoY) and growth rate of SEROQUEL XR and SEROQUEL IR 2014-2015 ($ millions)
Exhibit 30: Eli Lilly: Key highlights
Exhibit 31: Eli Lilly: Strength assessment
Exhibit 32: Eli Lilly: Strategy assessment
Exhibit 33: Eli Lilly: Opportunity assessment
Exhibit 34: GlaxoSmithKline: Strength assessment
Exhibit 35: GlaxoSmithKline: Strategy assessment
Exhibit 36: GlaxoSmithKline: Opportunity assessment
Exhibit 37: Johnson & Johnson: Key highlights
Exhibit 38: Johnson & Johnson: Strength assessment
Exhibit 39: Johnson & Johnson: Strategy assessment
Exhibit 40: Johnson & Johnson: Opportunity assessment
